VIGANO', OTTAVIA

VIGANO', OTTAVIA  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 20 di 20 (tempo di esecuzione: 0.002 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation 1-gen-2007 O. ViganoE. GianelliM. OrtuM. GalliS. Rusconi + Article (author) -
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral- experienced HIV-1-infected subjects treated with tenofovir combination therapy [2] 1-ott-2005 M. Lo CiceroO. ViganòP. CicconiM. GalliS. Rusconi + Article (author) -
Analysis of protease inhibitor combinations in vitro : activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates 1-mar-2004 E. BulgheroniP. CitterioF. CroceM. Lo CiceroO. ViganòM. GalliS. Rusconi + Article (author) -
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens 1-gen-2011 O. ViganòS. FerramoscaP. VitielloM. GalliS. Rusconi + Article (author) -
Does GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results 1-gen-2011 M. OrtuP. VitielloO. ViganòM. GalliS. Rusconi + Article (author) -
Efficacia di Caspofungin nella candidosi esofagea HIV-correlata multifarmacoresistente 1-gen-2002 P. CicconiM. PiazzaO. Vigano'F. TordatoR. PioliniM. MoroniS. Antinori + Article (author) -
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV : experience in a pediatric population 6-ago-2012 S. RusconiV. GiacometC. MameliO. ViganòM. GalliG.V. Zuccotti + Article (author) -
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients 1-nov-2014 O. ViganoE. ColellaM. GalliS. Rusconi + Article (author) -
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir 1-gen-2008 B. VerganiLO CICERO, MIRKOO. ViganòS. FerramoscaP. VitielloDI VINCENZO, PAOLAM. GalliS. Rusconi + Article (author) -
Female gender is associated with long COVID syndrome : a prospective cohort study 9-nov-2021 Bai F.Tomasoni D.Falcinella C.Barbanotti D.Castoldi R.Mule' G.Augello M.Mondatore D.Allegrini M.Cona A.Tesoro D.Tagliaferri G.Vigano' O.Suardi E.Tincati C.Beringheli T.Varisco B.Vegni E.Terzoni S.Marchetti G.D'Arminio Monforte A. + Article (author) -
Haemoptysis and fever in a young refugee from Somalia 1-ott-2018 Mondoni, MicheleViganò, OttaviaBIMBATTI, MANUELACAVALLINI, MIRTAD'Arminio Monforte, AntonellaBulfamante, GaetanoCentanni, Stefano + Article (author) -
New HIV protease inhibitors for drug-resistant viruses 1-gen-2006 S. RusconiO. Viganò Article (author) -
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses 22-mag-2009 S. RusconiM. Lo CiceroO. ViganòS. FerramoscaM. Galli + Article (author) -
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients 11-nov-2012 A. GiacomelliM. FranzettiB. VerganiM. MorosiV. Di CristoE. ColellaO. ViganòM. GalliS. Rusconi + Article (author) -
Resolution of multidrug-refractory oesophageal candidiasis in an AIDS patient after treatment with caspofungin 1-giu-2002 P. CicconiO. Vigano'S. Antinori + Article (author) -
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients : a randomized, controlled, pilot study (the REYAGEN study) 1-gen-2015 S. RusconiO. ViganòM. Galli + Article (author) -
Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an HIV-infected patient failing all four classes of antiretroviral drugs 1-mag-2008 O. Vigano'S. Rusconi + Article (author) -
Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatmentefficacy in UGT1A1*28 polymorphism carriers 1-set-2012 L. FerrarisO. ViganòA.M. PeriM. TarkowskiE.G.I. ClementiM. GalliA. Riva + Article (author) -
Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice 1-gen-2021 Falcinella, CamillaAllegrini, MarinaGazzola, LidiaMule, GiovanniTomasoni, DanieleVigano, Ottaviad'Arminio Monforte, AntonellaMarchetti, GiuliaTincati, Camilla Article (author) -
Unusual codon 69 insertions : influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility 1-gen-2004 E. BulgheroniF. CroceP. CitterioO. ViganòM. GalliS. Rusconi + Article (author) -